Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,614 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series.
Song Y, Connor DT, Doubleday R, Sorenson RJ, Sercel AD, Unangst PC, Roth BD, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD. Song Y, et al. Among authors: chan k. J Med Chem. 1999 Apr 8;42(7):1151-60. doi: 10.1021/jm9805081. J Med Chem. 1999. PMID: 10197959
Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
Song Y, Connor DT, Sercel AD, Sorenson RJ, Doubleday R, Unangst PC, Roth BD, Beylin VG, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD. Song Y, et al. Among authors: chan k. J Med Chem. 1999 Apr 8;42(7):1161-9. doi: 10.1021/jm980570y. J Med Chem. 1999. PMID: 10197960
Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C, Auclair E, Avenel N, Bertin B, Bigot C, Calvet A, Chan K, Durand C, Fasquelle V, Féru F, Gilbertsen R, Jacobelli H, Kebsi A, Lallier E, Maignel J, Martin B, Milano S, Ouagued M, Pascal Y, Pruniaux MP, Puaud J, Rocher MN, Terrasse C, Wrigglesworth R, Doherty AM. Burnouf C, et al. Among authors: chan k. J Med Chem. 2000 Dec 14;43(25):4850-67. doi: 10.1021/jm000315p. J Med Chem. 2000. PMID: 11123995
ASO Visual Abstract: Quality of Cancer Recurrence Data in the National Cancer Database: A Reappraisal of Reporting Readiness.
Chan K, Palis BE, Cotler JH, Janczewski LM, Zhu X, Boffa DJ, Park KU, Boughey JC, Plichta JK, In H, Nogueira LM, Yabroff RK, Hawhee VM, Merriman KW, Habermann EB, Williams VL, Mason K, Mullett TW, Weigel RJ, Nelson H. Chan K, et al. Ann Surg Oncol. 2025 Jan 27. doi: 10.1245/s10434-025-16901-0. Online ahead of print. Ann Surg Oncol. 2025. PMID: 39865204 No abstract available.
12,614 results
You have reached the last available page of results. Please see the User Guide for more information.